Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 |
| NCT04393753 | Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1(MERKLIN2) | completed | Phase 2 | 19 | 4SC AGINDUSTRY | 6 | May 8, 2024 | clinicaltrials |
| NCT03870399 | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression(HORMONET) | completed | Phase 2 | 23 | AC Camargo Cancer CenterOTHER | 2 | May 6, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04381910 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | completed | Phase 2 | 66 | Luye Pharma Group Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02155647 | Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) | completed | Phase 2 | 204 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Mar 13, 2024 | clinicaltrials |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT00020202 | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03012620 | Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 334 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03008369 | Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT00390325 | Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04361825 | Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects(SUKSES-N4) | completed | Phase 2 | 42 | Se-Hoon LeeOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT02399215 | Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 24 | Shadia Jalal, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02580994 | Pembrolizumab in Untreated Extensive SCLC(REACTION) | completed | Phase 2 | 125 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT02318784 | Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers | completed | Phase 2 | 62 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06155994 | 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | completed | Phase 1 / Phase 2 | 12 | Medical University InnsbruckOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT01782443 | Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 140 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02267603 | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2023 | clinicaltrials |
| NCT03043664 | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors(PLANET) | completed | Phase 1 / Phase 2 | 22 | Duke UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04385992 | Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET(NeoLuPaNET) | completed | Phase 2 | 31 | IRCCS San RaffaeleOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT01440816 | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer(MCC) | completed | Phase 2 | 15 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05858177 | The Efficacy and Safety of Temozolomide in Patients With MPPGL(MPPGL) | completed | Phase 2 | 62 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT00193531 | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT00442533 | Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors | completed | Phase 2 / Phase 3 | 200 | Radio Isotope Therapy of AmericaOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT01237457 | 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms | completed | Phase 2 | 143 | Ebrahim S DelpassandOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT01253161 | Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03079440 | TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | completed | Phase 2 | 31 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT01013779 | Merkel Positron Emission Tomography (PET) Protocol(MP3) | completed | Phase 2 | 43 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03590119 | Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases(LUTIA) | completed | Phase 2 / Phase 3 | 26 | Marnix LamOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03722511 | Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs | completed | Phase 2 | 10 | Lowell Anthony, MDOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02359019 | MK-3475 as Maintenance Therapy in Extensive Stage SCLC | completed | Phase 2 | 45 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02608203 | [68 Ga]-DOTANOC PET/CT in GEP-NETs(GEP-NOC) | completed | Phase 2 / Phase 3 | 18 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg(CLARINET FORTE) | completed | Phase 2 | 99 | IpsenINDUSTRY | 10 | Oct 3, 2022 | clinicaltrials |
| NCT02205515 | An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis(EBRT) | completed | Phase 1 / Phase 2 | 17 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT01371201 | First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma(FIRSTMAPPP) | completed | Phase 2 | 78 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 4 | Aug 4, 2022 | clinicaltrials |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma.(iTEP-CMT) | completed | Phase 1 / Phase 2 | 25 | Nantes University HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02945852 | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | completed | Phase 2 | 40 | Fan Yun, MDOTHER | 1 | Jul 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2024source: clinicaltrials